Conditional approval: discussion points from the PSI conditional approval expert group, Pharmaceutical Statistics, vol.254, issue.20, pp.263-269, 2008. ,
DOI : 10.1002/pst.309
Patient Registries: Utility, Validity and Inference, Adv Exp Med Biol, vol.686, pp.87-104, 2010. ,
DOI : 10.1007/978-90-481-9485-8_6
The frequency of lysosomal storage diseases in The Netherlands, Human Genetics, vol.105, issue.1-2, pp.151-156, 1999. ,
DOI : 10.1007/s004399900075
Prevalence of Lysosomal Storage Disorders, JAMA, vol.281, issue.3, pp.249-254, 1999. ,
DOI : 10.1001/jama.281.3.249
Prevalence of lysosomal storage diseases in Portugal, European Journal of Human Genetics, vol.12, issue.2, pp.87-92, 2004. ,
DOI : 10.1038/sj.ejhg.5201044
High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*, The American Journal of Human Genetics, vol.79, issue.1, pp.31-40, 2006. ,
DOI : 10.1086/504601
Disease Registries and Outcomes Research in Children, Pediatric Drugs, vol.144, issue.1, pp.33-47, 2011. ,
DOI : 10.2165/11586860-000000000-00000
alpha-Galactosidase A deficiency: Fabry disease. In The Metabolic and Molecular Bases of Inherited Disease, pp.3733-3774, 2001. ,
Vasculopathy in patients with Fabry disease: Current controversies and research directions, Molecular Genetics and Metabolism, vol.99, issue.2, pp.99-108, 2010. ,
DOI : 10.1016/j.ymgme.2009.10.004
Enzyme Replacement Therapy in Fabry Disease, JAMA, vol.285, issue.21, pp.2743-2749, 2001. ,
DOI : 10.1001/jama.285.21.2743
Safety and Efficacy of Recombinant Human ??-Galactosidase A Replacement Therapy in Fabry's Disease, New England Journal of Medicine, vol.345, issue.1, pp.9-16, 2001. ,
DOI : 10.1056/NEJM200107053450102
Natural history of Fabry disease in females in the Fabry Outcome Survey, Journal of Medical Genetics, vol.43, issue.4, pp.347-352, 2006. ,
DOI : 10.1136/jmg.2005.036327
Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry, Molecular Genetics and Metabolism, vol.93, issue.2, pp.112-128, 2008. ,
DOI : 10.1016/j.ymgme.2007.09.013
Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease: Natural History Data from the Fabry Registry, Clinical Journal of the American Society of Nephrology, vol.5, issue.12, pp.2220-2228, 2010. ,
DOI : 10.2215/CJN.04340510
Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey, Journal of Medical Genetics, vol.46, issue.8, pp.548-552, 2009. ,
DOI : 10.1136/jmg.2008.065904
URL : https://hal.archives-ouvertes.fr/hal-00552689
Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey, European Heart Journal, vol.28, issue.10, pp.1228-1235, 2007. ,
DOI : 10.1093/eurheartj/ehm153
Clinical manifestations of Fabry disease in children: Data from the Fabry Outcome Survey, Acta Paediatrica, vol.34, issue.1, pp.86-92, 2006. ,
DOI : 10.1080/08035250500275022
Fabry disease: overall effects of agalsidase alfa treatment, European Journal of Clinical Investigation, vol.327, issue.12, pp.838-882, 2004. ,
DOI : 10.1161/hs0202.102601
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data, The Lancet, vol.374, issue.9706, pp.1986-1996, 2009. ,
DOI : 10.1016/S0140-6736(09)61493-8
The value of estimated GFR in comparison to measured GFR for the assessment of renal function in adult patients with Fabry disease, Nephrology Dialysis Transplantation, vol.25, issue.8, pp.2549-2556, 2010. ,
DOI : 10.1093/ndt/gfq108
A systematic review of the clinical effectiveness and costeffectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1, Health Technol Assess, vol.10, pp.1-130, 2006. ,
Clinical benefit of enzyme replacement therapy in Fabry disease, Kidney International, vol.69, issue.7, pp.1216-1221, 2006. ,
DOI : 10.1038/sj.ki.5000208
Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg, PLoS ONE, vol.115, issue.7, p.598, 2007. ,
DOI : 10.1371/journal.pone.0000598.s003
Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy: Evidence for a Better Outcome With Early Treatment, Circulation, vol.119, issue.4, pp.524-529, 2009. ,
DOI : 10.1161/CIRCULATIONAHA.108.794529
Gaucher Disease In The Metabolic and Molecular Bases of Inherited Disease, pp.3635-3668, 2001. ,
The cost of treating Gaucher disease, Nature Medicine, vol.47, issue.5, pp.523-524, 1996. ,
DOI : 10.1016/S0140-6736(95)91037-9
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry, The American Journal of Medicine, vol.113, issue.2, pp.112-119, 2002. ,
DOI : 10.1016/S0002-9343(02)01150-6
The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease, Clinical Genetics, vol.104, issue.Suppl. 1, pp.205-211, 2007. ,
DOI : 10.1111/j.1399-0004.2007.00769.x
Eight-Year Clinical Outcomes of Long-Term Enzyme Replacement Therapy for 884 Children With Gaucher Disease Type 1, PEDIATRICS, vol.122, issue.6, pp.1182-1190, 2008. ,
DOI : 10.1542/peds.2007-2144
36. Dose???response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type I, Molecular Genetics and Metabolism, vol.93, issue.2, pp.92-100, 2009. ,
DOI : 10.1016/j.ymgme.2007.10.048
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review, Health Technology Assessment, vol.10, issue.24, pp.1-136, 2006. ,
DOI : 10.3310/hta10240
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis, The Lancet, vol.355, issue.9214, pp.1481-1486, 2000. ,
DOI : 10.1016/S0140-6736(00)02161-9
Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease, Blood Cells, Molecules, and Diseases, vol.44, issue.1, pp.41-47, 2010. ,
DOI : 10.1016/j.bcmd.2009.09.006